Effect of tumour necrosis factor-alpha and interleukin-6 promoter polymorphisms on course of Crimean-Congo hemorrhagic fever in Turkish patients

Journal of Vector Borne Diseases

Volumn 52, Issue 1, 2015, Pages 30-35

  Yilmaz, Meral ^a   Elaldi, Nazif ^a   Bagci, Binnur ^a   Sari, Ismail ^a   Gümüs, Erkan ^a   Yelkovan, Izzet ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Crimean congo hemorrhagic fever (CCHF); IL 6; Polymorphism; TNF

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GENOMIC DNA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME SIZE; GENOTYPE; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL RATE; TURK (PEOPLE); GENETICS; MIDDLE AGED; NAIROVIRUS; PATHOLOGY; TURKEY; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TUMOR NECROSIS FACTOR-ALPHA; TURKEY; YOUNG ADULT;

EID: 84925950062     PISSN: 09729062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64: 145–60.
2. Maltezou HC, Andonova L, Andraghelti R, Bouloy M, Ergonul Ö, Jongejan F, et al. Crimean-Congo hemorrhagic fever in Europe: Current situaiton calls for preparedness. Euro Surveill 2010; 15(10):19504.
3. Gunes T, Engin A, Poyraz O, Elaldi N, Kaya S, Dokmetas I,et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. Emerg Infect Dis 2009; 15: 461–464.
4. Onguru P, Dagdas S, Bodur H, Yilmaz M, Akinci E, Eren S, et al. Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its ralation with mortality. J Clin Lab Anal 2010; 24: 163–6.
5. Kwiatkowski D. Genetic dissection of the molecular pathogenesis of severe infection. Intensive Care Med 2000; 26 (Suppl 1): S89–97.
6. Qidwai T, F Khan. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol 2011; 74: 522–547.
7. Ishihara K, Hirano T. IL-6 autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357–68.
8. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11(Suppl 4): 794–800.
9. Ribeiro CSS, Visentainer JEL, Moliterno RA. Association of cytokine genetic polymorphism with hepatitis B infection evolution in adult patients. Mem Inst Oswaldo Cruz 2007; 102(4): 435–40.
10. Zhang YL, Dong L, Chen XF. Association of tumour necrosis factor-alpha -308G/A and interleukin-6-174G/C gene polymorphisms with the susceptibility of respiratory syncytial virus bronchiolitis. Zhongguo Dong Dai Er Ke Za Zhi 2009; 11(10): 821– 4.
11. Sobti RC, Berhane N, Mahedi SA, Kler R, Hosseini SA, et al. Polymorphisms of IL-6-174G/C, IL-10-592C/A and risk of HIV/ AIDS among north Indian population. Mol Cell Biochem 2010; 337: 145–52.
12. Fabris C, Toniutto P, Bitetto D, Fattovich G, Falleti E, Minisini R, et al. Gene polymorphism at the interleukin-6 -174G>C locus affects the outcome of chronic hepatitis B. J Med 2009; 59: 144– 5.
13. Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, Fantonini E, et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 2011; 63: 33–41.
14. Doyle WJ, Casselbrant ML, Li-Karotky HS, Doyle AP, Lo C-Y, Turner R, et al. The IL-6 (-174C/C) genotype predicts greater rhinovirus illness. J Infect Dis 2010; 201(2): 199–206.
15. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J. Polymorphisms in tumor necrosis factor-α, transforming growth factor-ß, interleukin-10, interleukin-6, interferon-γ and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212–8.
16. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ. Strong HLA class I—restricted T-cell responses in dengue hemorrhagic fever: A double-edged sword? J Infect Dis 2001; 184: 1369–73.
17. Vejbaesya S, Luangtrakool P, Luangtrakool K, Kalayanarooj S, Vaughn DW, Endy TP, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. J Infect Dis 2009; 199(10): 1442–8.
18. Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, Layrisse Z. TNF-α-308A allele, a possible severity risk factor of hemorrhagic manisfestation in dengue fever patients. Tissue Antigens 2004; 64: 469–72.
19. Perez AB, Sierra B, Garcia G, Aguirre E, Babel N, Alvarez M, et al. Tumor necrosis factor-alpha, transforming growth factor-ß1, and interleukin-10 gene polymorphisms: Implication in protection or susceptibility to dengue hemorrhagic fever. Human Immunol 2010; 71: 1135–40.
20. Makela S, Mustonen J, Ala-Houhala I, Hurme M, Partanen J, Vapalahti O, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-α (-308) G/A polymorphism. J Infect Dis 2002; 186: 843–6.
21. Meenagh A, Williams F, Ross OA, Patterson C, Gorodezky C, Hammond M, et al. Frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East and South America. Human Immunol 2002; 63: 1055–61.
22. Alhamad EH1, Cal JG, Shakoor Z, Almogren A. Cytokine gene polymorphisms of TNF-α, IL-6, IL-10 TGF-ß and IFN-γ in the Saudi population. Br J Biomed Sci 2013; 70(3): 104–9.
23. Bakir M, Engin A, Gozel MG, Elaldi N, Kilickap S, Cinar Z. A new perspective to determine the severity of cases with CrimeanCongo hemorrhagic fever. J Vector Borne Dis 2012; 49: 105– 10.
24. Kadanali A, Erol S, Özkurt Z, Özden K. Epidemiological risk factors for Crimaen-Congo hemorrhagic fever patients. Türk J Med Sci 2009; 39(6): 829–32.
25. Tasdelen Fisgin N, Tanyel E, Doganci L, Tulek N. Risk factors for fatality in patients with Crimean-Congo haemorrhagic fever. Trop Doct 2009; 39(3): 158–60.
26. Ergonul O1, Celikbas A, Baykam N, Eren S, Dokuzoguz B. : Analysis of risk-factors among patients with Crimean-Congo hemorrhagic fever virus infection Severity criteria revisited. Clin Microbiol Infect. 2006; 12(6): 551–4.